A Randomized Trial of Vaccine Adherence in Young IDU
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Medication Adherence
- Sponsor
- University of California, San Francisco
- Enrollment
- 546
- Locations
- 1
- Primary Endpoint
- Vaccine Series Completion
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this study is to compare the effects of (a) immunization setting and (b) outreach worker support on young injection drug users' (IDU) adherence to a multiple dose immunization schedule with a combined hepatitis A virus (HAV) inactivated and hepatitis B virus (HBV) recombinant vaccine.
Detailed Description
This is a research trial consisting of a cross-sectional screening study and a prospective cohort study (randomized, 2x2 factorial design). The primary aim of the study is to evaluate the effects of immunization setting and outreach worker support on young IDU's adherence to a multiple dose immunization schedule with a combined HAV and HBV vaccine. Secondarily, the study will 1) explore the feasibility of a remote immunization network and web-based vaccine registry to improve immunization coverage of transient young IDU, 2) examine the effect of hepatitis C virus (HCV) infection in vaccine effectiveness, and 3) assess behavior change and vaccine attitudes in young IDU participating in a preventive vaccine trial. Subjects in the screening study complete an interview, receive counseling and testing for HIV, HAV, HBV and HCV, and return in one week for test results and risk reduction counseling. Subjects eligible for the cohort study receive their first immunizations at enrollment and then are randomized to receive subsequent vaccines at either a set of syringe exchange programs (SEP) or at a public health adult immunization clinic (AIC). Subjects also are randomized to receive vaccine reminders from an outreach worker or no outreach worker support. Each subject receives a total of 4 immunizations over 6 months. Follow up visits include interviews, counseling, and viral testing. Study participation is for 12 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Vaccine Series Completion
Time Frame: 12 months
The primary outcome was the completion of the four-dose vaccine series in a 12 month period.
Secondary Outcomes
- HIV Vaccine Trial Willingness(Baseline)
- HIV Vaccine Trial Knowledge(Baseline)
- Hepatitis B Surface Antibody Seroconversion After 3 Vaccine Doses(12 months)
- Viral Transmission Risk Behavior Association With Travel(Baseline)